Display options
Cite
Rosenberg JH, Shafor R. Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Curr Neurol Neurosci Rep. 2005;5(2):140-6doi: 10.1007/s11910-005-0012-5.
Rosenberg, J. H., & Shafor, R. (2005). Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Current neurology and neuroscience reports, 5(2), 140-6. https://doi.org/10.1007/s11910-005-0012-5
Rosenberg, Jay H, and Shafor, Renata. "Fatigue in multiple sclerosis: a rational approach to evaluation and treatment." Current neurology and neuroscience reports vol. 5,2 (2005): 140-6. doi: https://doi.org/10.1007/s11910-005-0012-5
Rosenberg JH, Shafor R. Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Curr Neurol Neurosci Rep. 2005 Mar;5(2):140-6. doi: 10.1007/s11910-005-0012-5. PMID: 15743552.
Copy Download .nbib Format: NLM
Share it on

Curr Neurol Neurosci Rep. 2005 Mar;5(2):140-6. doi: 10.1007/s11910-005-0012-5.

Fatigue in multiple sclerosis: a rational approach to evaluation and treatment.

Current neurology and neuroscience reports

Jay H Rosenberg, Renata Shafor

Affiliations

  1. The Neurology Center, 9850 Genesee, Suite 220, La Jolla, CA 92037, USA. [email protected]

PMID: 15743552 DOI: 10.1007/s11910-005-0012-5

Abstract

With the publication of the Multiple Sclerosis Council Guideline on the management of multiple sclerosis (MS) fatigue, there has been increased appreciation for the role fatigue can play in MS. Secondary fatigue is fatigue caused by other etiologies than those directly related to MS. Once these causes are ruled out, fatigue is related to MS. Secondary MS-related fatigue comes as result of the symptoms of MS that drain energy. Once secondary MS causes are ruled out, then the patient is deemed as having primary MS fatigue. Fatigue management is both nonpharmacologic and pharmacologic. Occupational therapists are the major allied health providers that address the role fatigue plays in MS patients. Over the past two decades, numerous clinical trials have been conducted on drugs for treating MS-related fatigue. Of these agents, amantadine has been studied for the longest period, and has shown efficacy in about one third of patients with MS-related fatigue on several commonly used scales. Two randomized -trials of the central nervous system stimulant pemoline have yielded unimpressive results; efficacy was seen at higher doses but coupled with an unacceptable risk of adverse events. The wake-promoting agent modafinil is the only agent to show efficacy compared with placebo on the Fatigue Severity Scale, a measure that is highly resistant to "impulse answering" and is thus viewed as one of the most difficult scales on which to show -benefit. This article reviews fatigue in MS and proposes a rational strategy for evaluation and management of this most common MS symptom.

References

  1. Psychoneuroendocrinology. 2003 Aug;28(6):780-95 - PubMed
  2. Sleep. 1999 Sep 15;22(6):757-65 - PubMed
  3. J Neuropsychiatry Clin Neurosci. 1993 Spring;5(2):200-5 - PubMed
  4. J Neurol. 2002 Aug;249(8):983-7 - PubMed
  5. Respiration. 1997;64(2):159-61 - PubMed
  6. Sleep. 1991 Dec;14(6):540-5 - PubMed
  7. Int J Neurosci. 1995 Dec;83(3-4):153-63 - PubMed
  8. Can J Neurol Sci. 1987 Aug;14(3):273-8 - PubMed
  9. J Neurosci. 2000 Nov 15;20(22):8620-8 - PubMed
  10. Arch Phys Med Rehabil. 1988 Oct;69(10):846-9 - PubMed
  11. Tissue Antigens. 1995 Oct;46(4):333-6 - PubMed
  12. Arch Gen Psychiatry. 1961 Jun;4:561-71 - PubMed
  13. Neurology. 1991 Mar;41(3):447-8 - PubMed
  14. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14128-33 - PubMed
  15. J Neurol. 1993 Jul;240(7):446-8 - PubMed
  16. J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-83 - PubMed
  17. Eur Neurol. 1994;34(6):320-3 - PubMed
  18. Arch Neurol. 1992 May;49(5):517-24 - PubMed
  19. Neurology. 1995 Nov;45(11):1956-61 - PubMed
  20. J Sleep Res. 1995 Dec;4(4):212-228 - PubMed
  21. Neurology. 2000 Mar 14;54(5):1166-75 - PubMed
  22. Neurology. 1992 Aug;42(8):1468-71 - PubMed
  23. Can J Neurol Sci. 1985 Aug;12(3):251-4 - PubMed
  24. J Psychosom Res. 1993 May;37(4):325-31 - PubMed
  25. Neurology. 1997 Jun;48(6):1566-71 - PubMed
  26. Arch Neurol. 1989 Jun;46(6):676-80 - PubMed

MeSH terms

Publication Types